There is a critical shortage of PEGASYS (peginterferon alfa-2a) injection due to manufacturing disruptions. This shortage presents serious risks to patients in Canada who depend on interferon-based therapy for treating myeloproliferative neoplasms (MPNs). Although PEGASYS is not authorized by Health Canada for this use, it has been prescribed off-label for this condition. Given the critical medical need, Health Canada has permitted the exceptional, temporary importation and sale of a similar but not identical product, US-authorized BESREMi (ropeginterferon alfa-2b-njft), injection with English-only labels by FORUS Therapeutics Inc.
RecallTracker